PAO Group, Inc.’s CBD Nutraceuticals Expected To Deliver
Revenue-Generating Catalyst in 2021; New Partnerships Expand Its
Long-Term CBD Pharmaceutical Programs
Miami Beach, Fl -- May 11, 2021 -- InvestorsHub NewsWire -- via
Hawk Point Media -- PAO Group, Inc. (USOTC: PAOG) is
getting nearer to its first of several planned revenue-generating
catalysts. Last week, in addition to announcing new partnerships,
PAOG offered a sneak peek at its upcoming CBD Nutraceuticals line
of products. The excellent news is that at its current pace of
development, PAOG expects revenue from the CBD Nutraceutical line
later this year and, at the same time, accelerate its long-term
projects involving CBD pharmaceuticals.
PAOG’s flagship product is expected to be RespRx, a
development-stage CBD pharmaceutical product derived from a
patented cannabis extraction method. Once launched, it targets a
massive billion-dollar Chronic Obstructive Pulmonary Disorder
(COPD). The better news is that PAOG has plenty more in its
pipeline.
In fact, PAOG intends to launch three CBD nutraceuticals as soon
as the fourth quarter of FY-2021. Their first CBD Nutraceutical in
production will be named CBD RELAX-RX and is designed to target the
anxiety and depression treatment market. That product is targeting
an expected $18 billion market by 2025. The second CBD
Nutraceutical in production will come from PAOG’s ongoing COPD
studies, which will focus on the COPD treatment market separately
from the overall pharmaceutical sector. The third CBD Nutraceutical
is being produced in collaboration with the EVERx CBD Sports Water
brand owned by Puration, Inc. (USOTC:
PURA) and will be marketed to the sports nutrition
industry.
To develop and sell the CBD nutraceuticals, PAOG intends to work
with Alkame Holdings, Inc. (OTC
Pink: ALKM) as a co-developer and North American Cannabis
Holdings, Inc. (OTC
Pink: USMJ) as a distributor. Both offer logistical and
industry expertise to the program.
Video Link: https://www.youtube.com/embed/mlG8HDv06uk
PAO Group, With A CRO On Its Side, Could Deliver Its
First CBD-Based Therapeutic By Year’s End
Notably, PAO Group may be able to expedite its ongoing CBD
Pharmaceutical Development Program thanks to recently introduced
laws pertaining to cannabis legalization. The loosening of
restrictions and regulatory oversight could work in PAOG’s favor in
bringing its products to market more quickly. What’s even better,
the easing regulations could open the door to new research partners
and potential investors who have previously been reluctant to work
in the sector under current laws. Changes could help PAOG from more
than just a regulatory standpoint; they could also clear a pathway
to significant growth in the second half of 2021.
Another factor driving PAOG’s growth will be its ability to
maximize its partnership with Puration, Inc. in building a
pharmaceutical-grade indoor hemp grow facility and CBD extraction
facility in conjunction with PURA’s Farmersville Hemp Brand project
in Texas.
And, with the timeline to legalization getting shorter, its
agreements to expedite growth are happening at the right time.
Thus, interest in PAOG’s CBD-based pipeline is likely to grow in
the back half of this year.
The sector is experiencing a dynamic shift in sentiment. And at
least 99% of it brings positive implications for
PAOG.
PAOG Can Capitalize on Changing Laws
The Texas House of Representatives passed a bill to relax
marijuana restrictions in April, particularly for CBD-based
therapeutics, PAOG’s primary focus. Alongside this bill, a popular
financial publication generated considerable buzz through an
article titled, “President Joe Biden is in favor of decriminalizing
marijuana, while Senate Majority Leader Chuck Schumer is ready to
push ahead with full legalization efforts even if Biden isn’t
completely on board just yet.” The article cites data from a recent
Pew Research study that demonstrates overwhelming public support
for legalization, “91% of people in the U.S. believe marijuana
should be legal for either medical or recreational use, with 60% in
favor of both.” While both may help PAOG in various ways, the
therapeutics side of the equation should be most exciting for the
company and its investors.
In 2020, PAOG struck a deal with Kali-Extracts, Inc. (OTC
Pink: KALY) to acquire RespRx, a CBD treatment for chronic
obstructive pulmonary disease (COPD) being developed using a
proprietary cannabis extraction process. In a synergistic move to
further develop this treatment, PAOG bolstered its portfolio by
hiring Veristat, a contract research organization (CRO) committed
to the scientific advancement of therapies and treatments through
regulatory approval.
With the expected relaxation of regulations and CRO Veristat on
its team, PAOG has created an excellent foundation for a breakout
year in 2021. Already, things are looking good.
2021 Could be a Year of Growth
From a valuation perspective, 2021 has been good for PAOG. Since
January of this year, shares are up by approximately 219%. A report
outlining its efforts to extend its CBD-based therapeutics and
nutraceuticals program received positive feedback from investors.
As noted, at least two treatment candidates are currently being
developed by the company, aimed at large and potentially lucrative
markets. Together, the two treatment candidates target a combined
market opportunity estimated to be valued as high as $25 billion
within the next five years. The estimates continue to surge after
that period.
The great news is that Veristat, a contract research
organization (CRO) committed to the scientific advancement of
therapies and treatments through regulatory approval, may deliver a
significant boost to the opportunity.
Veristat has already made significant strides in validating and
supplementing the underlying research for RespRx, according to an
update from PAOG. This is undoubtedly positive news for the short
term, while future updates on commercialization progress could
pique market interest for the long-term play.
Interest is building already. In April of this year, the stock
attempted to break resistance but unfortunately came up short,
hitting a wall at $0.01. Despite this, any milestone updates
released concerning its new RespRx program could soon give PAOG a
more robust second attempt. If that wall is broken, the next stop
could be near $0.02, representing a near 200% gain from current
levels.
Upcoming Research Funding Will Open New
Opportunities
PAOG also announced in April that it expects to finalize an
agreement that will include research funding and a 25% interest in
a cannabis extraction patent. More good news came next, with the
company announcing that it is in final talks to form a partnership
to perform a CBD In Vivo Histological Research Study, which would
help RespRx get regulatory approval faster. The 25% stake in the
underlying proprietary cannabis extraction technology, from which
the RespRx formula is extracted, could provide PAOG with a
company-changing asset. PAOG also noted that it could secure the
right to buy the patent outright in the long term, which would open
up a variety of new revenue streams.
The patent, at face value, could become a substantial
revenue-generating asset for PAOG. The company has stated that
industry experts agree its extraction method produces an extract
very similar to that of GW Pharma (NASDAQ: GWPH), a
leading figure in the development of CBD-based treatments. All
things considered, this means that PAOG could monetize the
commodity by licenses and agreements without ever bringing a
product to the lab, allowing the company to harvest any windfalls
without ever getting a product to market. This is a long-term
strategy that could eventually bring substantial revenues – and
don’t believe PAOG is oblivious of its strong hand, especially
after GW Pharma’s acquisition by Jazz Pharmaceuticals
(NASDAQ: JAZZ) for
$7.2 billion earlier this year.
It all combines toward a potentially massive year for the
company.
A Bullish Outlook In 2H 2021
Although the pandemic has slowed program growth in industries
worldwide, PAOG is far from stalled. In fact, some of the most
significant developments for the company happened throughout the
last year, as the company secured the work of Veristat, acquired a
new asset, and built upon its business relationships in Puerto Rico
to expedite its research and development processes.
In fact, PAOG could be in its strongest position ever to build
shareholder value in the coming weeks and months, with two
therapeutics in the works and a proposed extension of its
development programs. Moreover, the intrinsic value alone from its
asset base is already more valuable than its current share price.
Not only does this help to mitigate some of the risks associated
with a long-term investment, but any one of the many planned
near-term updates could drive valuations considerably
higher.
On PAO Group, the investment thesis is simple. The company has
positioned itself to have multiple shots on goal, has engaged with
a CRO to expedite planned approvals, and has partnerships and
acquisition strategies all working on adding value to the
stock.
The best news is that development at any level could spark a
potentially huge second half of 2021. And if all goes according to
plan, PAOG investors could benefit from both near and long-term
catalysts that drive investment returns now and potentially bigger
ones later.
Disclaimers: Hawk Point Media is responsible for the
production and distribution of this content. Hawk Point Media is
not operated by a licensed broker, a dealer, or a registered
investment adviser. It should be expressly understood that under no
circumstances does any information published herein represent a
recommendation to buy or sell a security. Our
reports/releases are a commercial advertisement and are for general
information purposes ONLY. We are engaged in the business of
marketing and advertising companies for monetary compensation.
Never invest in any stock featured on our site or emails unless you
can afford to lose your entire investment. The
information made available by Hawk Point Media is not intended to
be, nor does it constitute, investment advice or recommendations.
The contributors may buy and sell securities before and after any
particular article, report and publication. In no event shall Hawk
Point Media be liable to any member, guest or third party for any
damages of any kind arising out of the use of any content or other
material published or made available by Hawk Point Media,
including, without limitation, any investment losses, lost profits,
lost opportunity, special, incidental, indirect, consequential or
punitive damages. Past performance is a poor indicator of future
performance. The information in this video, article, and in its
related newsletters, is not intended to be, nor does it constitute,
investment advice or recommendations. Hawk Point
Media strongly urges you conduct a complete and
independent investigation of the respective companies and
consideration of all pertinent risks. Readers are advised to review
SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports,
Forms 3, 4, 5 Schedule 13D. For some content, Hawk Point Media, its
authors, contributors, or its agents, may be compensated for
preparing research, video graphics, and editorial content. As part
of that content, readers, subscribers, and website viewers, are
expected to read the full disclaimers and financial disclosures
statement that can be found by clicking HERE.
The Private Securities Litigation Reform Act of 1995
provides investors a safe harbor in regard to forward-looking
statements. Any statements that express or involve discussions with
respect to predictions, expectations, beliefs, plans, projections,
objectives, goals, assumptions or future events or performance are
not statements of historical fact may be forward looking
statements. Forward looking statements are based on expectations,
estimates, and projections at the time the statements are made that
involve a number of risks and uncertainties which could cause
actual results or events to differ materially from those presently
anticipated. Forward looking statements in this action may be
identified through use of words such as projects, foresee, expects,
will, anticipates, estimates, believes, understands, or that by
statements indicating certain actions & quote; may, could, or
might occur. Understand there is no guarantee past performance will
be indicative of future results.Investing in micro-cap and
growth securities is highly speculative and carries an extremely
high degree of risk. It is possible that an investors investment
may be lost or impaired due to the speculative nature of the
companies profiled.
Media Contact
Company Name: Hawk Point Media
Contact Person: KL Feigeles
Email: Send
Email
City: Miami Beach
State: Florida
Country: United States
Website: https://www.greenlightstocks.com
Source: https://www.getnews.info/1128555/pao-group-incs-cbd-nutraceuticals-expected-to-deliver-revenuegenerating-catalyst-in-2021-new-partnerships-expand-its-longterm-cbd-pharmaceutical-programs.html#ixzz6uYs8GWBq
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Sep 2023 to Sep 2024